Suppr超能文献

医院手术量对晚期上皮性卵巢癌初次肿瘤细胞减灭术后完全大体切除(CGR)率的影响。

Impact of hospital surgical volume on complete gross resection (CGR) rates following primary debulking surgery for advanced stage epithelial ovarian carcinoma.

机构信息

Division of Gynecologic Oncology, University of Pennsylvania Health System, Philadelphia, PA, USA.

Division of Gynecologic Oncology, Weill Cornell Medicine, NY, New York, USA.

出版信息

Gynecol Oncol. 2019 Aug;154(2):401-404. doi: 10.1016/j.ygyno.2019.05.016. Epub 2019 May 31.

Abstract

BACKGROUND

To investigate the impact of hospital surgical volume on the rate of complete gross resection for patients with advanced stage epithelial ovarian carcinoma undergoing primary debulking surgery.

METHODS

The National Cancer Data Base was used to identify patients undergoing between 2010 and 2014 for an advanced stage (III-IV) epithelial ovarian cancer. For analyses purposes facility surgical volume was divided into tertiles (high, intermediate and low). Patients with bulky stage III disease who underwent primary debulking surgery with known residual disease status were selected for further analysis.

RESULTS

A total of 8894 patients with macroscopic peritoneal disease were included. Rates of complete gross resection for patients managed in low, intermediate and high-volume centers were 41.0%, 41.6% and 43.3% respectively (p = 0.20). After controlling for year of diagnosis, age, insurance status, presence of co-morbidities, histology, size of peritoneal implants, stage, and complexity of surgery, patients undergoing primary debulking surgery at low (OR: 0.85, 95% CI: 0.74, 0.97, p = 0.013) and intermediate (OR: 0.90, 95% CI: 0.82, 0.99, p = 0.043) volume centers had a lower likelihood of achieving complete gross resection compared to those managed in high volume centers.

CONCLUSIONS

After controlling for multiple potential confounders, patients receiving surgery in high volume centers had a higher likelihood of complete gross resection following primary debulking surgery for advanced-stage epithelial ovarian cancer.

摘要

背景

调查医院手术量对接受初次肿瘤细胞减灭术的晚期上皮性卵巢癌患者完全大体切除率的影响。

方法

利用国家癌症数据库,确定 2010 年至 2014 年间接受晚期(III-IV 期)上皮性卵巢癌治疗的患者。出于分析目的,将医院手术量分为三分位数(高、中、低)。选择接受已知残留疾病状态的大型 III 期疾病患者进行进一步分析。

结果

共纳入 8894 例有腹膜疾病的患者。在低、中、高容量中心接受治疗的患者完全大体切除率分别为 41.0%、41.6%和 43.3%(p=0.20)。在控制诊断年份、年龄、保险状况、合并症、组织学、腹膜种植大小、分期和手术复杂性后,在低(OR:0.85,95%CI:0.74,0.97,p=0.013)和中(OR:0.90,95%CI:0.82,0.99,p=0.043)容量中心接受初次肿瘤细胞减灭术的患者完全大体切除的可能性低于在高容量中心接受治疗的患者。

结论

在控制多个潜在混杂因素后,在高容量中心接受手术的患者在接受晚期上皮性卵巢癌初次肿瘤细胞减灭术后完全大体切除的可能性更高。

相似文献

2
A novel classification of residual disease after interval debulking surgery for advanced-stage ovarian cancer to better distinguish oncologic outcome.
Am J Obstet Gynecol. 2019 Oct;221(4):326.e1-326.e7. doi: 10.1016/j.ajog.2019.05.006. Epub 2019 May 10.
3
Ascites volume at the time of primary debulking and overall survival of patients with advanced epithelial ovarian cancer.
Int J Gynecol Cancer. 2021 Dec;31(12):1579-1583. doi: 10.1136/ijgc-2021-002978. Epub 2021 Oct 26.
4
6
Survival outcomes after delayed cytoreduction surgery following neoadjuvant chemotherapy in advanced epithelial ovarian cancer.
Int J Gynecol Cancer. 2020 Dec;30(12):1935-1942. doi: 10.1136/ijgc-2020-001658. Epub 2020 Oct 29.
9
Impact of residual disease at interval debulking surgery on platinum resistance and patterns of recurrence for advanced-stage ovarian cancer.
Int J Gynecol Cancer. 2021 Oct;31(10):1341-1347. doi: 10.1136/ijgc-2020-001505. Epub 2021 Aug 24.

引用本文的文献

1
Correlation of surgical volume in gynecological cancer centers with the quality of ovarian cancer care.
J Cancer Res Clin Oncol. 2025 Aug 28;151(8):239. doi: 10.1007/s00432-025-06288-6.
2
Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: ASCO Guideline Update.
J Clin Oncol. 2025 Mar;43(7):868-891. doi: 10.1200/JCO-24-02589. Epub 2025 Jan 22.
3
Regionalizing ovarian cancer cytoreduction to high-volume centers and the impact on patient travel in New York State.
Gynecol Oncol. 2024 Mar;182:141-147. doi: 10.1016/j.ygyno.2024.01.004. Epub 2024 Jan 22.
4
Surgery in Advanced Ovary Cancer: Primary versus Interval Cytoreduction.
Diagnostics (Basel). 2022 Apr 14;12(4):988. doi: 10.3390/diagnostics12040988.
5
Trends in extent of surgical cytoreduction for patients with ovarian cancer.
PLoS One. 2021 Dec 8;16(12):e0260255. doi: 10.1371/journal.pone.0260255. eCollection 2021.
6
miR‑508‑3p suppresses the development of ovarian carcinoma by targeting CCNA2 and MMP7.
Int J Oncol. 2020 Jul;57(1):264-276. doi: 10.3892/ijo.2020.5055. Epub 2020 Apr 27.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验